July 29, 2009 – At the AAPM 51st Annual Meeting, Calypso Medical Technologies touted its strategic development agreement with Varian Medical Systems to jointly develop products integrating its Calypso System with Varian’s radiotherapy treatment technologies.
Calypso Medical’s proprietary technology utilizes miniature implanted transponders to provide precise, continuous, real-time information about the location of the tumor target during external beam radiation therapy. Calypso’s technology provides continuous tumor position information designed to enable the correct radiation dose to be delivered to the tumor while minimizing the amount of radiation misapplied to normal tissue.
The Calypso technology is complementary to Varian’s state-of-the-art technology for delivering intensity-modulated radiotherapy (IMRT), including RapidArc radiotherapy. Varian is the market share leader for linear accelerators worldwide.
“This strategic development agreement will facilitate advanced treatment capabilities through the integration of the Calypso System with Varian’s market-leading radiotherapy technologies,” said Eric R. Meier, president and chief executive officer of Calypso Medical. “We believe these efforts may prove beneficial for prostate patients as well as some of the more difficult radiation therapy targets such as pancreas and lung. In the near term, two exciting joint development efforts will integrate the motion management capabilities of our Calypso System with Varian’s state-of-the-art treatment platform. This agreement will provide the framework for the joint development of Real-Time MLC Tracking, a future capability* demonstrated by both companies last year, which causes the radiation beam to move in concert with the tumor target based on real-time tracking data provided by the Calypso System.”
Under the terms of the agreement, the two companies will jointly develop products that integrate the Calypso System with Varian’s technologies. Further terms of the agreement were not disclosed.
* This technology is a concept device under development and not available for sale.
For more information: www.calypsomedical.com
April 29, 2024 
